• Earlier in May 2026, BioMarin reported that its Phase 3 CANOPY-HCH-3 trial of VOXZOGO in children with hypochondroplasia met its primary endpoint, showing a statistically significant 2.33 cm/year gain in annualized growth velocity over placebo and meaningful improvements in arm span with a safety profile consistent with prior use in achondroplasia.
• Because hypochondroplasia currently has no approved therapies, these data and BioMarin’s plan to file a supplemental FDA application in the third quarter of 2026 highlight VOXZOGO’s potential to address an additional rare growth disorder with significant unmet medical need.
• With VOXZOGO now showing Phase 3 efficacy in hypochondroplasia, we’ll examine how this potential label expansion could reshape BioMarin’s investment narrative.

Find 48 companies with promising cash flow potential yet trading below their fair value.

BioMarin Pharmaceutical Investment Narrative Recap

To own BioMarin today, you need to believe its rare disease portfolio, led by VOXZOGO, can keep justifying premium pricing despite rising costs and regulatory complexity. The hypochondroplasia Phase 3 win reinforces VOXZOGO’s role in that story and adds a near term sNDA catalyst, but it does not remove the core risks around pricing pressure, pipeline execution and reliance on a few key products.

The CANOPY HCH 3 success lands only days after mixed Phase 3 results for BMN 401 in ENPP1 deficiency, where biochemical benefit did not translate into clear clinical gains. That contrast underscores how much BioMarin’s growth narrative still hinges on VOXZOGO label expansions and future readouts, while reminding investors that not every late stage asset will necessarily convert into a durable commercial driver.

Yet against this strong VOXZOGO update, investors still need to be aware that pricing pressure and payer pushback could...

BioMarin Pharmaceutical's narrative projects $4.9 billion revenue and $1.3 billion earnings by 2029. This requires 14.7% yearly revenue growth and roughly a $1.0 billion earnings increase from $268.7 million today.

Uncover how BioMarin Pharmaceutical's forecasts yield a $89.96 fair value, a 66% upside to its current price.

Exploring Other Perspectives

While the consensus view leans on VOXZOGO expansion, the lowest estimate analysts were assuming about US$4.8 billion of revenue and US$1.1 billion of earnings by 2029, and they focus much more on the risk that heavy dependence on a few therapies could collide with tougher pricing and reimbursement, so this new trial success may or may not soften that more cautious stance once forecasts are updated.

Explore 4 other fair value estimates on BioMarin Pharmaceutical - why the stock might be worth over 3x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your BioMarin Pharmaceutical research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free BioMarin Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioMarin Pharmaceutical's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.
• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.